Teddi Mellencamp Reveals Shocking Truth Behind Doctors Missing Melanoma Spreading
Thankfully, Teddi is finally turning the corner on her battle. Her body responded positively to immunotherapy. The remaining tumors in her brain and lungs either disappeared or shrank. But with that good news, Teddi also reflected on whether doctors could have caught the cancer before it spread.
Teddi Mellencamp's doctors missed her melanoma spreading
Teddi gave an exclusive interview with Glamour on July 17 to update fans on her situation. She stressed the importance of advocating to doctors and being proactive. In her case, the routine checkups weren't enough to catch the cancer spread earlier on.
'When you go to a doctor, you just assume that's it. I'm doing what I'm supposed to do,' the RHOBH alum said. 'At first, I didn't even really do the research on melanoma because I didn't want to know all of the bad things. But there's a difference between self-diagnosing yourself and being an advocate for your own health.'
Teddi continued, 'I never really thought about it because I was like, 'I go to a doctor every three months. Why wouldn't they get me checked?' My highest melanoma on my shoulder was stage one. When I finally followed up on it, they were like, 'We didn't do the scans, because you didn't have anything above a stage one on your body.' But look what happened.'
Teddi has had 17 surgeries to remove melanoma spots since 2022. In February 2025, tumors were discovered on her brain and lungs, leading to radical change in strategy. The former Bravolebrity had chemotherapy and immunotherapy treatment.
Catch The Real Housewives of Beverly Hills streaming on Peacock and Hayu in the UK and Ireland.
TELL US – WHAT IS YOUR REACTION TO HER COMMENTS?
The post Teddi Mellencamp Reveals Shocking Truth Behind Doctors Missing Melanoma Spreading appeared first on Reality Tea.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
CNN
44 minutes ago
- CNN
WSJ: Kennedy expected to dismiss expert panel on preventive care
Federal agencies WellnessFacebookTweetLink Follow US Health and Human Services Secretary Robert F. Kennedy Jr. plans to remove the expert advisers who make up a federal panel on preventive health care, the Wall Street Journal reported Friday. The future of the US Preventive Services Task Force has been in doubt since HHS called off this month's meeting of the nonpolitical advisory group. 'No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again,' HHS spokesperson Andrew Nixon told CNN on Friday. The 16-member task force was established in 1984 and provides recommendations about preventive services, such as screenings for cancer and various disorders and counseling, that help make Americans aware of illnesses and conditions earlier, when they can be easier and less expensive to treat. The Affordable Care Act mandates that those services are provided without charge to patients. Kennedy's control over the task force was recently solidified by the US Supreme Court. Last month, in a case challenging a popular provision of the Affordable Care Act, the justices upheld the constitutionality of the task force, which recommends preventive health care services that insurers must cover at no cost. Both the Biden and Trump administrations argued that the task force was properly set up — and therefore, its recommendations should be upheld — because the Health and Human Services secretary was able to name and fire its members. Since taking over at HHS, Kennedy has pushed to reshape the health agencies and expunge them of what he has called longtime health-care industry influence on policies. Last month, he dismissed the 17-member vaccine advisory committee for the US Centers for Disease Control and Prevention and, two days later, named eight new picks. Several of the new members of the Advisory Committee on Immunization Practices have questioned vaccine safety; two have testified in court against vaccine manufacturers.
